Skip to main content

AddLife AB (publ) (ALIF-B.ST)

Euronext Healthcare Medical - Instruments & SuppliesView data quality →
53.6Fair

ValueMarkers Composite Index

Top 49%#22,804 of 44,707
Overvalued

49% above intrinsic value ($11)

UndervaluedFair ValueOvervalued
Piotroski
8/9
Strong
Beneish
-3.35
Low Risk
Altman
2.53
Grey Zone
DCF Value
$11
Overvalued
ROIC
5.4%
Low
P/E
34.0
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

AddLife AB (publ) (ALIF-B.ST) — VMCI valuation read

AddLife AB (publ) sits at VMCI 54/100, with the Healthcare sector median at 50. That 4-point spread is the first thing to note on ALIF-B.ST: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on ALIF-B.ST are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on ALIF-B.ST: ALIF-B.ST trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of 2.6x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

ALIF-B.ST fell 2.8% over the trailing 7 days, with a -23.4% read on a 30-day basis.

AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.

CEO: Fredrik Dalborg2,251 employeesSEwww.add.life

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in ALIF-B.ST’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.